ASSOCIATION BETWEEN LIPODYSTROPHY AND LEPTIN IN HUMAN IMMUNODEFICIENCY VIRUS-1-INFECTED CHILDREN RECEIVING LOPINAVIR/RITONAVIR-BASED THERAPY

Highly active antiretroviral therapy might lead to the development of dyslipidemia and lipodystrophy (LD) syndrome. We carried out a multicenter prospective study of 22 human immunodeficiency virus (HIV)-1-infected children treated during 48 months with lopinavir/ritonavir-based highly active antiretroviral therapy to evaluate the trend of serum lipids and adipokines. Increase in plasma leptin levels and leptin/adiponectin ratio was associated with LD. These adipokines may be surrogate markers of LD.